[A16-57] Nivolumab (NSCLC) - Addendum to Commission A16-25
Last updated 20.10.2016
Commission awarded on 05.09.2016 by the Federal Joint Committee (G-BA).
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
|A18-40||Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)||Commission completed|
|A16-25||Nivolumab (new therapeutic indication) – Benefit assessment according to §35a SGB V||Commission completed|
|A21-89||Nivolumab (malignant pleural mesothelioma) - Benefit assessment according to §35a Social Code Book V||Commission completed|
Federal Joint Committee (G-BA)
2016-10-20 A G-BA decision was published.